Review article
Thrombotic microangiopathies in bone marrow and organ transplant patients
Bruce C. McLeod,
Corresponding Author
Bruce C. McLeod
Rush Medical College and Rush Presbyterian St. Luke's Medical Center, Chicago, Illinois
Rush Medical College and Rush Presbyterian St. Luke's Medical Center, 1753 W. Congress Parkway, Chicago, IL 60612Search for more papers by this authorBruce C. McLeod,
Corresponding Author
Bruce C. McLeod
Rush Medical College and Rush Presbyterian St. Luke's Medical Center, Chicago, Illinois
Rush Medical College and Rush Presbyterian St. Luke's Medical Center, 1753 W. Congress Parkway, Chicago, IL 60612Search for more papers by this author
REFERENCES
- 1 Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: A hitherto undescribed disease. Proc NY Pathol Soc 1924; 24: 21–24.
- 2 Gasser C, Gautier E, Steck A, Siebenmann RE, Dechslin R. Hämolytisch-urämische Syndrome: Bilaterale Nierenrindennekrosen bei akuten erworbenen hämolytischen Anämien. Schweiz Med Wochenschr 1955; 85: 905–909.
- 3 Remuzzi G. HUS and TTP: Variable expression of a single entity. Kid Int 1987; 32: 292–308.
- 4 Murgo AJ. Thrombotic microangiopathy in the cancer patient including those induced by chemotherapeutic agents. Semin Hematol 1987; 24: 161–177.
- 5 Gordon LI, Kwaan HC, Rossi EC. Deleterious effects of platelet transfusions and recovery thrombosis in patients with thrombotic microangiopathy. Semin Hematol 1987; 24: 194–201.
- 6 George JN. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood 2000; 96: 1223–12229.
- 7 Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578–1584.
- 8 Tsai H, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585–1594.
- 9 Furlan M, Robles R, Solenthaler M, et al. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89: 3097–3103.
- 10 Furlan M, Lämmle B. Haemolytic-uraemic syndrome and thrombotic thrombocytopenic purpura: new insights into underlying biochemical mechanisms. Nephrol Dial Transplant 2000; 15: 1112–1114.
- 11 Veyradier A, Obert B, Houllier A, Meyer D, Girma J-P. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 2001; 98: 1765–1772.
- 12 Pettitt AR, Clark RE. Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplant 1994; 14: 495–504.
- 13 Roy V, Rizvi MA, Vesely SK, George JN. Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes. Bone Marrow Transplant 2001; 27: 641–646.
- 14 Zeigler ZR, Shadduck RK, Nemunaitis J, Andrews DF, Rosenfeld CS. Bone marrow transplant-associated thrombotic microangiopathy: a case series. Bone Marrow Transplant 1995; 15: 247–253.
- 15 Schriber JR, Jerzig GP. Transplantation-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol 1997; 34: 126–133.
- 16 Paquette RL, Tran L, Landaw EM. Thrombotic microangiopathy following allogeneic bone marrow transplantation is associated with intensive graft-versus-host disease prophylaxis. Bone Marrow Transplant 1998; 22: 351–357.
- 17 Jacopino P, Pucci G, Arese W, et al. Gruppo Italiano Trapianto Midollo Osseo (GITMO). Severe thrombotic microangiopathy: an infrequent complication of bone marrow transplantation. Bone Marrow Transplant 1999; 24: 47–51.
- 18 Fuge R, Bird JM, Fraser A, et al. The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation. Br J Haematol 2001; 113: 58–64.
- 19 van der Plas RM, Schiphorst ME, Huizinga EG, et al. von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombo- cytopenia purpura. Blood 1999; 93: 3798–3802.
- 20 Zeigler Z, Kelton J, Moore J, et al. Calpain activity in bone marrow transplant-associated thrombotic thrombocytopenic purpura. Bone Marrow Transplant 1999; 24: 641–645.
- 21 Natazuka T, Kajimoto K, Ogawa R, et al. Coagulation abnormalities and thrombotic microangiopathy following bone marrow transplantation from HLA-matched unrelated donors in patients with hematological malignancies. Bone Marrow Transplant 1998; 21: 815–819.
- 22
Anthony MT,
Zeigler ZR,
Lister J, et al.
Plasminogen activator inhibitor (PAI-1) antigen levels in primary TTP and secondary TTP post-bone marrow transplantation.
Am J Hematol
1998;
59:
9–14.
10.1002/(SICI)1096-8652(199809)59:1<9::AID-AJH3>3.0.CO;2-T CAS PubMed Web of Science® Google Scholar
- 23 Plews DE, Turner ML, Wallace WH. Plasma exchange as successful treatment of thrombotic thrombocytopenic purpura post autologous bone marrow transplant in a child. Bone Marrow Transplant 2000; 25: 679–680.
- 24 Milone J, Napal J, Bordone J, Etchegoyen O, Morales V. Complete response in severe thrombotic microangiopathy post bone marrow transplantation after multiple plasmaphereses. Bone Marrow Transplant 1998; 22: 1019–1021.
- 25 Kolker O, Sviri S, Linton DM, et al. Plasmapheresis for thrombotic thrombocytopenic purpura following bone marrow transplantation. Acta Haematol 2001; 105: 156–158.
- 26 Sarode R, McFarland JG, Flomenber N, et al. Therapeutic plasma exchange does not appear to be effective in the management of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome following bone marrow transplantation. Bone Marrow Transplant 1995; 16: 271–275.
- 27 Lahlou A, Lang P, Charpentier B, et al. Hemolytic uremic syndrome. Recurrence after renal transplantation. Groupe Cooperatif de I'lle-de-France (GCIF). Medicine 2000; 79: 90–102.
- 28 Mihatsch MJ, Kyo M, Morozumi K, et al. The side-effects of ciclosporine-A and tacrolimus. Clin Nephrol 1998; 49: 356–363.
- 29 Kohler TR, Tilney. Microangiopathic hemolytic anemia associated with hyperacute rejection of a kidney allograft. Transplant Proc 1982; 15: 444–447.
- 30 Mor E, Lustig S, Tovar A, et al. Thrombotic microangiopathy early after kidney transplantation: hemolytic uremic syndrome or vascular rejection? Transplant Proc 2000; 32: 686–687.
- 31
Winters JL,
Pineda AA,
McLeod BC,
Grima KM.
Therapeutic apheresis in renal and metabolic diseases.
J Clin Apheresis
2000;
15:
53–73.
10.1002/(SICI)1098-1101(2000)15:1/2<53::AID-JCA5>3.0.CO;2-W CAS PubMed Web of Science® Google Scholar
- 32 Dundas S, Murphy J, Soutar RL, et al. Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157:H7 outbreak. Lancet 1999; 354: 1327–1330.
- 33 Carter AO, Borczyk AA, Carlson JAC, et al. A severe outbreak of Escherichia coli O157:H7-associated hemorrhagic colitis in a nursing home. N Engl J Med 1987; 24: 1496–500.
- 34 Pichette V, Querin S, Schurch W, et al. Familial hemolytic uremic syndrome and homozygous factor H deficiency. Am J Kidney Dis 1994; 24: 936–941.
- 35 Warwicker P, Goodship THJ, Donne RL, et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 1998; 53: 836–844.
- 36 Riggenenti P, Remuzzi G. Treatment of adult hemolytic-uremic syndrome. Adv Nephrol Necker Hosp 2000; 30: 83–94.
- 37 Singh N, Gayowski T, Marino I. Hemolytic uremic syndrome in solid-organ transplant recipients. Transpl Int 1996; 9: 68–75.
- 38 Humar A, Jessurun J, Sharp HL, et al. Thrombotic microangiopathy after liver-small bowel transplant. Clin Transplant 1998; 12: 600–601.
- 39 Van Buren D, Van Buren CT, Flechner SM, et al. De novo hemolytic uremic syndrome in renal transplant recipients immunosuppressed with cyclosporine. Surgery 1985; 98: 54–62.
- 40 Franz M, Regele H, Schmaldienst S, et al. Posttransplant hemolytic uremic syndrome in adult retransplanted kidney graft recipients: advantage of FK506 therapy? Transplantation 1998; 66: 1258–1262.
- 41 Myers JN, Shabshab SF, Burton NA, et al. Successful use of cyclosporine in a lung transplant recipient with tacrolimus-associated hemolytic uremic syndrome. J Heart Lung Transplant 1999; 18: 1029–1026.
- 42 McGregor DO, Robson RA, Lynn KL. Haemolytic-uremic syndrome in a renal transplant recipient treated by conversion to mycophenolate mofetil. Nephron 1998; 80: 365–366.
- 43 Brown Z, Neild GH, Willoughby JJ, Somia NV, Cameron SJ. Increased Factor VIII as an index of vascular injury in cyclosporine nephrotoxicity. Transplantation 1986: 42: 150–153.
- 44 Yoshida M, Kozaki M, Ioya N, et al. Plasma thrombomodulin levels as an indicator of vascular injury caused by cyclosporine nephrotoxicity. Transplantation 1990; 50: 1066–1069.
- 45 Zoja K, Furci L, Ghilardi F, et al. Cyclosporin-induced endothelial cell injury. Laboratory Investigation 1985; 55: 455–462.
- 46 Grace AA, Barradas MA, Mikhailidis DP, Jeremy JY, et al. Cyclosporine A enhances platelet aggregation. Kid Int 1987; 32: 889–895.
Citing Literature
